Vertex Pharmaceuticals (VRTX) Competitors $484.24 +3.91 (+0.81%) Closing price 04:00 PM EasternExtended Trading$486.92 +2.68 (+0.55%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VRTX vs. AMGN, GILD, REGN, ALNY, BIIB, UTHR, INCY, BMRN, NBIX, and EXELShould you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Vertex Pharmaceuticals vs. Amgen Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends. Do insiders and institutionals hold more shares of VRTX or AMGN? 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, VRTX or AMGN? Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVertex Pharmaceuticals$11.02B11.28-$535.60M-$2.20-220.11Amgen$33.42B4.87$4.09B$7.5540.13 Do analysts rate VRTX or AMGN? Vertex Pharmaceuticals presently has a consensus target price of $505.61, suggesting a potential upside of 4.41%. Amgen has a consensus target price of $314.09, suggesting a potential upside of 3.66%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vertex Pharmaceuticals 0 Sell rating(s) 10 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.65Amgen 2 Sell rating(s) 10 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.46 Does the MarketBeat Community believe in VRTX or AMGN? Vertex Pharmaceuticals received 51 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.06% of users gave Vertex Pharmaceuticals an outperform vote while only 72.03% of users gave Amgen an outperform vote. CompanyUnderperformOutperformVertex PharmaceuticalsOutperform Votes160175.06% Underperform Votes53224.94% AmgenOutperform Votes155072.03% Underperform Votes60227.97% Is VRTX or AMGN more profitable? Amgen has a net margin of 12.24% compared to Vertex Pharmaceuticals' net margin of -4.86%. Amgen's return on equity of 176.32% beat Vertex Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vertex Pharmaceuticals-4.86% -2.02% -1.49% Amgen 12.24%176.32%11.71% Which has more risk & volatility, VRTX or AMGN? Vertex Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Does the media refer more to VRTX or AMGN? In the previous week, Amgen had 3 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 57 mentions for Amgen and 54 mentions for Vertex Pharmaceuticals. Amgen's average media sentiment score of 1.57 beat Vertex Pharmaceuticals' score of 1.20 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 43 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 52 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryAmgen beats Vertex Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRTX vs. The Competition Export to ExcelMetricVertex PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.35B$7.04B$5.77B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-220.116.1326.4918.81Price / Sales11.28314.26449.1576.66Price / CashN/A67.8344.0437.47Price / Book7.586.747.634.64Net Income-$535.60M$138.11M$3.18B$245.69M7 Day Performance5.50%-2.02%-1.82%-2.64%1 Month Performance13.17%-1.54%0.22%-2.37%1 Year Performance15.40%-3.14%17.49%13.63% Vertex Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRTXVertex Pharmaceuticals4.1401 of 5 stars$484.24+0.8%$505.61+4.4%+14.2%$124.35B$11.02B-220.116,100Analyst DowngradeInsider TradeAnalyst RevisionPositive NewsAMGNAmgen4.4691 of 5 stars$291.16-2.0%$314.09+7.9%+5.1%$156.51B$33.42B38.5626,700Positive NewsGILDGilead Sciences4.7856 of 5 stars$104.08-1.8%$101.33-2.6%+52.7%$129.71B$27.12B1,156.4418,000Analyst UpgradeInsider TradeOptions VolumeAnalyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.6242 of 5 stars$673.60-0.1%$973.13+44.5%-26.5%$74.02B$14.20B17.6013,450Dividend AnnouncementALNYAlnylam Pharmaceuticals4.5256 of 5 stars$256.45-3.2%$299.43+16.8%+68.7%$33.08B$1.83B-97.882,100Analyst ForecastInsider TradeBIIBBiogen4.7552 of 5 stars$137.33-0.8%$211.96+54.3%-37.5%$20.01B$9.84B12.417,570Analyst ForecastUTHRUnited Therapeutics4.3817 of 5 stars$370.58+0.0%$382.08+3.1%+71.5%$16.55B$2.33B16.271,168Insider TradeINCYIncyte4.5409 of 5 stars$70.42+0.6%$75.59+7.3%+21.4%$13.57B$3.70B503.042,524BMRNBioMarin Pharmaceutical4.9211 of 5 stars$64.85+0.7%$94.20+45.3%-22.5%$12.36B$2.42B38.833,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNBIXNeurocrine Biosciences4.9754 of 5 stars$115.02-1.6%$166.90+45.1%-12.5%$11.65B$2.36B34.961,400Analyst DowngradeAnalyst RevisionGap UpEXELExelixis4.6474 of 5 stars$35.00+1.5%$37.24+6.4%+70.1%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeGap Up Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
